Document Detail


Ranolazine Reduces Ventricular Tachycardia Burden and ICD Shocks in Patients with Drug-Refractory ICD Shocks.
MedLine Citation:
PMID:  21895727     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Background:  There are limited options for patients who present with antiarrhythmic-drug (AAD)-refractory ventricular tachycardia (VT) with recurrent implantable cardioverter defibrillator (ICD) shocks. Ranolazine is a drug that exerts antianginal and antiischemic effects and also acts as an antiarrhythmic in isolation and in combination with other class III medications. Ranolazine may be an option for recurrent AAD-refractory ICD shocks secondary to VT, but its efficacy, outcomes, and tolerance are unknown. Methods and Results:  Twelve patients (age 65 ± 9.7 years) were treated with ranolazine. Eleven (92%) were male, and 10 (83%) had ischemic heart disease with an average ejection fraction of 0.34 ± 0.13. All patients were on a class III AAD (11 amiodarone, one sotalol), with six (50%) receiving mexilitene or lidocaine. Five patients had a prior ablation and two were referred for a VT ablation at the index presentation. The QRS increased nonsignificantly from 128 ± 31 ms to 133 ± 31 ms, and the QTc increased nonsignificantly from 486 ± 32 ms to 495 ± 31 ms after ranolazine initiation. Over a follow-up of 6 ± 6 months, 11 (92%) patients had a significant reduction in VT and no ICD shocks were observed. VT ablation was not required in those referred. In two patients, gastrointestinal side effects limited long-term use. Of these two patients, one died due to progressive heart failure. In one patient, severe hypoglycemia limited dosing to 500 mg daily, but this was sufficient for VT control. Conclusion:  Ranolazine proved effective in reducing VT burden and ICD shocks in patients with AAD-refractory VT. Ranolazine should be further tested for this indication and considered for clinical application when other options have proven ineffective. (PACE 2011;1-7).
Authors:
T Jared Bunch; Srijoy Mahapatra; David Murdock; Jamie Molden; J Peter Weiss; Heidi T May; Tami L Bair; Katy M Mader; Brian G Crandall; John D Day; Jeffrey S Osborn; Joseph B Muhlestein; Donald L Lappe; Jeffrey L Anderson
Related Documents :
22917707 - Increased production of circulating soluble co-stimulatory molecules ctla-4, cd28 and c...
22810367 - Serum vitronectin levels in patients with behçet's disease.
22343347 - Complications of cirrhosis.
21632817 - Cardiac dimensions are largely determined by dietary salt in patients with primary aldo...
8348487 - Clinical significance of dysplasia in gastric remnant biopsy specimens.
22917707 - Increased production of circulating soluble co-stimulatory molecules ctla-4, cd28 and c...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-9-3
Journal Detail:
Title:  Pacing and clinical electrophysiology : PACE     Volume:  -     ISSN:  1540-8159     ISO Abbreviation:  -     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-9-7     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7803944     Medline TA:  Pacing Clin Electrophysiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
©2011, The Authors. Journal compilation ©2011 Wiley Periodicals, Inc.
Affiliation:
Intermountain Heart Rhythm Specialists Department of Cardiology, Intermountain Medical Center, Murray, Utah Division of Cardiovascular Medicine, University of Virginia, Charlottesville, Virginia Aspirus Wausau Hospital, Wausau, Wisconsin Dixie Regional Medical Center, St. George, Utah.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Left Ventricular Pacing in Right Ventricular Cardiomyopathy: Blessing or Blunder?
Next Document:  Radiofrequency Catheter Ablation of Posterior Paraseptal Accessory Pathway with Atresia of the Coron...